Benefits of bringing a PERI Corporate Education Course to your Organization

PERI’s Corporate Education Programs are customized courses presented at your facility. Courses are tailored to meet your company’s specific training needs and objectives. For more than 10 years, PERI has consistently provided the highest level of on-site education to the biopharmaceutical and medical device industries. PERI’s Corporate Education clients include over 350 pharmaceutical, biotechnology and government organizations.

Cost Effective: You can save time and money by having PERI train a group of 10 or more team members at the location of your choosing. Reduce travel expenses, time away from work and more with training on-site or at a nearby location.

Customized Programs Developed By Expert Faculty: Courses are designed to address the specific needs of your company by expert PERI faculty, many of which have years of industry and educational experience.

Corporate Education Courses

Additional features of corporate education courses:

  • All of PERI’s courses are available as Corporate Education Programs
  • Discounts are available for multiple courses (same course or series)
  • Programs can offer continuing education credits for physicians, pharmacists and other professionals
  • Programs can be presented to virtual audiences via webinar or webcast
  • New program development is PERI’s specialty!

Request a Proposal

Submit an RFP and a PERI course manager will be in touch.

Request Proposal






Request Proposal

Your Name (required)

Your Title (required)

Your Company (required)

Your Email (required)

Your Phone(required)

Subject of Interest(required)

Additional Information
(# Attendees, Location, Live/Online Learning, etc.)

How did you hear about us?

Testimonials

  • “The knowledge and background I learned helps me build relatedness and a sense of collaboration when I interact with people in domains outside of my expertise.”

  • “I better understand the drug development process and can have a positive impact in moving the drug product through the research pipeline.”